WISCONSIN DEPARTMENT OF HEALTH SERVICES · Tested Positive % Positive CoV-229E CoV-OC43 CoV-NL63...
Transcript of WISCONSIN DEPARTMENT OF HEALTH SERVICES · Tested Positive % Positive CoV-229E CoV-OC43 CoV-NL63...
1
WISCONSIN DEPARTMENT OF HEALTH SERVICES Division of Public Health
Bureau of Communicable Diseases
Respiratory virus surveillance report for the week ending October 24, 2015 week 42-15
AT-A-GLANCE • Respiratory viruses identified this week :
rhinovirus and parainfluenza viruses are predominant this week. Sporadic cases of influenza A and adenovirus were also identified.
• Influenza-like illness (ILI) activity for this week
Wisconsin Low Wisconsin (CDC level) Low Northwestern Region Low Northeastern Region Low Southeastern Region Low Southern Region Low
• ILI activity in Region V of the U.S. (WI, MN, IL, MI, OH, IN) is below baseline levels • ILI activity in the U.S. is below baseline levels • The Predictive Value Positive (PVP) for rapid influenza and RSV tests is: Low (PVP is the probability of disease in a patient with a positive test result) • The Predictive Value Negative (PVN) for rapid influenza and RSV tests is: High
(PVN is the probability of not having disease when the test result is negative) • Influenza-associated pediatric deaths reported (October 10, 2015-present) Week 42-15 Total to Date Wisconsin 0 0 Nationwide 0 0
2
WISCONSIN and REGIONAL SUMMARIES (Trend analysis based on 3-week moving averages)
Wisconsin (ILI activity is Low)
INFLUENZA RAPID ANTIGEN TESTS RSV RAPID ANTIGEN TESTS INFLUENZA-LIKE ILLNESS
Tested
Positive % Positive
Tested
Positive
% Positive
ILI %
Baseline
Threshold
Flu A Flu B Total 518 6 0 6 1.2% 86 1 1.2% 1.9% 2.0% 3.1%
Northwestern Region (ILI activity is Low)
INFLUENZA RAPID ANTIGEN TESTS RSV RAPID ANTIGEN TESTS INFLUENZA-LIKE ILLNESS
Tested
Positive % Positive
Tested
Positive
% Positive
ILI %
Baseline
Threshold
Flu A Flu B Total 85 3 0 3 1.2% 13 0 0% 1.0% 1.3% 2.1%
Influenza and RSV Trend (Rapid Tests)
0%
4%
8%
12%
16%
20%
9/19
10/3
10/1
7
10/3
1
11/1
4
week ending
Ave
rage
% P
ositi
ve
Influenza RSV
Average RSV Average Influenza
ILI Activity Trend Analysis
0%
2%
4%
6%
8%
9/19
10/3
10/1
7
10/3
1
11/1
4
week ending
Ave
rage
% IL
I
ILI % Baseline
Threshold Average ILI %
Influenza and RSV Trend Analysis (Lab)
0%
4%
8%
12%
16%
20%
9/19
10/3
10/1
7
10/3
1
11/1
4
week ending
Ave
rage
% P
ositi
ve
Influenza RSV
Average RSV Average Influenza
ILI Activity Trend Analysis
0%
2%
4%
6%
8%
9/19
10/3
10/1
7
10/3
1
11/1
4
week ending
Ave
rage
% IL
I
ILI % Baseline
Threshold Average ILI %
3
Northeastern Region (ILI activity is Low
INFLUENZA RAPID ANTIGEN TESTS RSV RAPID ANTIGEN TESTS INFLUENZA-LIKE ILLNESS
Tested
Positive % Positive
Tested
Positive
% Positive
ILI %
Baseline
Threshold
Flu A Flu B Total 119 1 0 1 0.8% 15 0 0% 0.7% 1.0% 1.7%
Southern Region (ILI activity is Low)
INFLUENZA RAPID ANTIGEN TESTS RSV RAPID ANTIGEN TESTS INFLUENZA-LIKE ILLNESS
Tested
Positive % Positive
Tested
Positive
% Positive
ILI %
Baseline
Threshold
Flu A Flu B Total 35 0 0 0 0% 3 0 0% 1.5% 2.5% 3.9%
Influenza and RSV Trend Analysis (Lab)
0%
4%
8%
12%
16%
20%
9/19
10/3
10/1
7
10/3
1
11/1
4
week ending
Ave
rage
% P
ositi
ve
Influenza RSV
Average RSV Average Influenza
Influenza and RSV Trend Analysis (Lab)
0%
4%
8%
12%
16%
20%
9/19
10/3
10/1
7
10/3
1
11/1
4
week ending
Ave
rage
% P
ositi
ve
Influenza RSV
Average RSV Average Influenza
ILI Activity Trend Analysis
0%
2%
4%
6%
8%
9/19
10/3
10/1
7
10/3
1
11/1
4
week endingA
vera
ge %
ILI
ILI % Baseline
Threshold Average ILI %
ILI Activity Trend Analysis
0%
2%
4%
6%
8%
9/19
10/3
10/1
7
10/3
1
11/1
4
week ending
Ave
rage
% IL
I
ILI % Baseline
Threshold Average ILI %
4
Southeastern Region (ILI activity is Low)
INFLUENZA RAPID ANTIGEN TESTS RSV RAPID ANTIGEN TESTS INFLUENZA-LIKE ILLNESS
Tested
Positive % Positive
Tested
Positive
% Positive
ILI %
Baseline
Threshold
Flu A Flu B Total 250 2 0 2 0.8% 26 1 3.8% 2.3% 1.0% 1.8%
For the 2015-16 influenza season, data from the Western Region and the Northern Region will be combined and referred to as the Northwestern Region. This change was made in response to the small number of providers who participate in our weekly surveillance in the Northern Region. Influenza Vaccine Composition 2015-2016
The trivalent vaccines for use in the 2015-2016 influenza season) contain the following:
• A/California/7/2009 (H1N1)pdm09-like virus; • A/Switzerland/9715293/2013 (H3N2)-like virus; • B/Phuket/3073/2013-like virus (Yamagata lineage).
It is recommended that quadrivalent vaccines containing two influenza B viruses contain the above three viruses and
• B/Brisbane/60/2008-like virus (Victoria Lineage)
Influenza and RSV Trend Analysis (Lab)
0%
4%
8%
12%
16%
20%
9/19
10/3
10/1
7
10/3
1
11/1
4
week ending
Ave
rage
% P
ositi
ve
Influenza RSV
Average RSV Average Influenza
ILI Activity Trend Analysis
0%
2%
4%
6%
8%
9/19
10/3
10/1
7
10/3
1
11/1
4
week endingA
vera
ge %
ILI
ILI % Baseline
Threshold Average ILI %
5
Wisconsin Positive Influenza Results PCR
0
5
10
15
20
25
30
19-S
ep
3-O
ct
17-O
ct
# P
ositi
ve D
etec
tions
0%
15%
30%
45%
60%
% p
ositi
ve
2009/H1 A/H3
A/unk B% positive 3 per. Mov. Avg. (% positive)
LABORATORY SURVEILLANCE FOR RESPIRATORY VIRUSES (PCR)
Respiratory Agent
Tested Positive % Positive
Flu A
Flu B
H3 pd2009 H1 Unk Yamagata Victoria Unk
Influenza 629 3 0.5% 2 0 1 0 0 0
Respiratory Agent
Tested Positive % Positive PI-1 PI-2 PI-3 PI-4
Parainfluenza 351 21 6.0% 13 0 1 7
Respiratory Agent
Tested Positive % Positive CoV-229E CoV-OC43 CoV-NL63 CoV-HKU1
Coronavirus 171 0 0% 0 0 0 0
Respiratory Agent
Tested Positive % Positive
1.1% RSV 389 2 0.5%
Human Metapneumovirus 336 0 0%
Rhino-entero 304 71 23.4% Adenovirus 171 3 1.8%
Trends in Respiratory Virus Activity PCR
using a 3-week moving average
0%
10%
20%
30%
19-S
ep
3-O
ct
17-O
ct
31-O
ct
14-N
ov
week ending
% p
ositi
ve
Cumulative number of positive influenza tests By subtype, September 1, 2015 to present
Influenza A Influenza B
Total pd2009 H1 H3 Unknown Yamagata Victoria Unknown Total
Number positive
1 16 9 2 1 2 31
% of Total
number positive
3% 52% 29% 6% 3% 6% 100%
6
Influenza-associated Hospitalizations, September 1, 2015 to present
Influenza-associated Hospitalizations by Public Health Region,
September 1, 2015 to present
Region Week 42 Season Total
Southeastern 0 2
Southern 0 6
Northeastern 3 11
Western 0 1
Northern 0 1
Wisconsin 0 21
Incidence/100,00 IIN I Incidence/100,000 Age
group
Wisconsin
National
<1 1 to 4 0 to 4
5 to 17 18 to 49 50 to 64
65+ total
Age
group Total
Number Reported (2015-16)
Influenza Subtypes Not
reported Admitted
to ICU Required
Mechanical Ventilation
Pregnant Females 2009
H1N1 H3N2 A/Unknown B
< 1 year 0 0 0 0 0 0 0 0
1 to 4 0 0 0 0 0 0 0 0
5 to 17 1 0 0 1 0 0 0 0
18 to
49 3 0 0 2 1 1 1 0 1
50 to
64 2 0 0 2 0 0 0 0
65 and over 15 0 2 8 4 1 1 0
Total 21 0 2 13 5 1 2 0 1
7
NATIONAL INFLUENZA SURVEILLANCE
8
Influenza characterization data will resume in November, 2015.
Influenza antiviral resistance data will resume in November, 2015.
State and Territorial reports will resume in October, 2015
Influenza-like illness indicator map will resume in October, 2015.
9
Seasonal Influenza Vaccination in Wisconsin Based on Doses Reported to the Wisconsin Immunization Registry (WIR)
October 30, 2015
Data for 2015-2016 Season Reported for 8.1.15-10.29.15
10
11
• These graphs include only doses of seasonal influenza vaccine administered and reported to the Wisconsin
Immunization Registry (WIR). • Data for 2015-16 season is incomplete because of the expected lag between the vaccine administration date and the date
reported to the WIR, which may be a short as one day or as long as several months, depending on the submitter. Therefore, the current season’s data will be adjusted as additional data is received.
12
• While use of the WIR is not mandatory, the WIR receives data from a variety of sources, including health care providers, health maintenance organizations, local health departments and tribal health centers/clinics, schools and pharmacies.
• For additional information regarding the immunization data, please contact Ashley Petit, epidemiologist, with the Wisconsin Immunization Program at (608) 266-7797.